$0.133
-0.002 (-1.63%)終値時点
VVOS のニュース
VVOS のイベント
Vivos Therapeutics Receives Nasdaq Compliance Notice
Vivos Therapeutics announced receipt of a letter from the Listing Qualifications staff of Nasdaq on October 20 stating that the company currently complies with Listing Rule 5550(b)(1), requiring the company to maintain stockholders' equity of at least $2.5M. The company previously reported the closing of its acquisition of an 11% fully diluted equity interest in SOD Sciences and a 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test. As part of the transaction, the company issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12M, which is expected to increase stockholders' equity by more than $10M. "While the company regained compliance with the stockholders' equity requirement following the closing of the transaction with SOD, we continue executing our strategy to maintain compliance and grow our business," said Kirk Huntsman, chairman and CEO.
Vivos Therapeutics Acquires 11% Stake in SOD Sciences for $12M
Vivos Therapeutics announced that it has entered into a definitive mutual stock purchase and asset exchange agreement to acquire an 11% fully diluted equity interest in SOD Sciences and a 50% undivided co-ownership interest in SOD's proprietary pseudohypoxia early-warning test, in exchange for 12,000 shares of newly created series C convertible preferred stock with an aggregate stated value of $12M. Closing is subject to customary conditions, including auditor concurrence, consent of the holder of the company's series B non-convertible preferred stock, and Nasdaq notification, and is expected to occur on or about October 15. No cash consideration is payable under the agreement. The company believes the transaction would increase reported stockholders' equity and support the company's efforts to regain compliance with Nasdaq rules. The preferred stock is convertible into shares of common stock at a fixed conversion price of 15c per share, representing up to 80M shares in the aggregate, subject to a 19.99% exchange cap pending stockholder approval.
Vivos Therapeutics Implements Restructuring Plan, Expected to Save $3.6M Annually
Vivos Therapeutics announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6M annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in the fourth quarter of 2026. In addition to the announced expense reductions, management has also pursued a number of revenue growth initiatives that are beginning to deliver meaningful financial returns.
Vivos Therapeutics Signs Collaboration Agreement with SPCVA to Establish Sleep Center
Vivos Therapeutics announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, or SPCVA, to support the establishment and operation of a regional Sleep & Airway Medicine Center, or SAMC, in Palm Beach County, Florida. The definitive agreements build on the collaboration announced on June 10 and provide the framework for the formation, capitalization, governance and operation of AIM Florida. Vivos expects to hold a 75% majority of the membership and economic interests in AIM Florida, subject to applicable regulatory requirements and the terms of the definitive agreements. The parties are evaluating several potential locations and negotiating a lease for the initial facility. Subject to site selection, lease execution, build-out, licensing, payer enrollment, staffing and other customary startup requirements, the center is expected to begin treating patients and generating revenue in the first quarter of 2027. The operating plan calls for an initial fully staffed Sleep Optimization Team capable of serving approximately 250 patients per month. Based on its operating experience in Las Vegas and current assumptions, Vivos believes the initial team, once fully deployed, can generate up to $6M in annual revenue with contribution margins of 30% or more. Additional teams may be added as demand develops. SPCVA doctors and staff will work to expand the referral base to include other local medical practices treating patients with similar sleep disorder issues.
Vivos Therapeutics Sees 212% Increase in New Patient Referrals
Vivos Therapeutics announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period. Since June 1, the total average weekly number of referrals has risen nearly five-fold and has continued to grow week over week. The company recently announced the grand opening on August 27 of its new 8,100 square feet sleep testing and treatment facility in Henderson, Nevada. The Henderson practice previously operated within a limited physical space, yet in two of the past three months, it recorded its highest total collections to date. The company expects revenue from its Henderson operations to grow further once the new facility becomes fully operational next week.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。